All In Biotech

Drug Trial Radar · NCT05442060

To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

A Randomized, Open-Label, Phase 2 Study to Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Aug 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jul 27, 2022

Primary completion

Dec 31, 2025

Study completion May 31, 2026

Sponsor

Lead sponsor
OBI Pharma, IncIndustry
Sponsor type
Industry
First posted
Jul 1, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a randomized, active control, open-label, phase 2 trial. Erlotinib-treated NSCLC patients will be screened for Globo H, and only Globo H+ (H score ≥ 100) subjects are eligible for the study. Eligible subjects who have been treated with 3±1 months of first-line erlotinib and have achieved stable disease (SD) or partial response (PR) status will be randomized in the ratio of 1:1 to receive erlotinib alone or erlotinib plus OBI-833/OBI-821 therapy.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • 30 μg OBI-833/100 μg OBI-821Biological

    Each subject in the OBI-833/OBI-821 + erlotinib combination arm will be treated with OBI-833/OBI-821 weekly for 4 doses (Weeks 1, 2, 3, 4), then every 2 weeks for 2 doses (Weeks 6, 8), then every 4 weeks for 4 doses (Weeks 12, 16, 20, 24), and then every 8 weeks until documented disease progression, intolerable adverse events (AEs)/toxicity, consent withdrawal, death, loss to follow-up, or up to 80 weeks from randomization.

  • Erlotinib (150 mg daily)Drug

    All subjects in both arms will continue to receive erlotinib as the background therapy (150 mg daily).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival rated at one yearTime frame: One year

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Taichung Veterans General Hospital

    Taichung, Taiwan · Recruiting

  • Taipei Veterans General Hospital

    Taipei, Beitou District, Taiwan · Recruiting

  • National Taiwan University Cancer Center

    Taipei, Da'an Dist., Taiwan · Recruiting

  • Linkou Chang Gung Memorial Hospital

    Taoyuan, Guishan Dist., Taiwan · Recruiting

  • Tri-Service General Hospital

    Taipei, Neihu District, Taiwan · Recruiting

  • Shuang Ho Hospital

    New Taipei City, Zhonghe District, Taiwan · Recruiting

  • National Taiwan University Hospital

    Taipei, Zhongzheng Dist., Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.